COVID-19 Research Program

A Leading Edge COVID-19 Response

On March 6th, 2020, Algernon announced that it was going to explore the potential of using NP-120 (Ifenprodil) as a novel treatment for COVID-19, also known as the coronavirus. An independent research study found that Ifenprodil significantly reduced acute lung injury and improved survivability in an animal study with H5N1 infected mice. H5N1 is the most lethal form of influenza known to date with an over 50% mortality rate. The study can be found here:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906739/

On June 4, 2020 Algernon received clearance from the U.S. FDA for its IND application for a 150 patient multi-national Phase 2b/3 clinical study of Ifenprodil & COVID-19 and enrolled its first patient on August 3.

Algernon receives clearance from the U.S. FDA 

On December 24, 2020, Algernon announced that the last patient from the Phase 2b part of the Ifenprodil COVID-19 study had completed both the treatment period and two week follow up and has announced that the final data set will be available at the end of February.

Algernon announces last patient

Click below for more detailed information on our Ifenprodil CIOVD-19 research program:

Christopher J. Moreau
Chief Executive Officer

Mark Williams, PhD, MBA
Chief Science Officer

Algernon’s COVID-19 Research and Response

Algernon’s Ifenprodil Background

click here to read more

Independent Ifenprodil Studies

click here to read more

Additional NP-120 (Ifenprodil) and Media Information

More data on NP-120 (Ifenprodil)

click here to read more

Digital Media Articles and Video Interviews

click here to read more

News and Investor Resources

click here to read more

Additional Global COVID-19 Media

(coming soon)
Share via
Copy link
Powered by Social Snap